Impact of safety-related dose reductions or discontinuations on sustained virologic response in HCV-infected patients: Results from the GUARD-C Cohort

GUARD-C Study Group Investigators

Research output: Article

3 Citations (Scopus)

Abstract

Background: Despite the introduction of direct-acting antiviral agents for chronic hepatitis C virus (HCV) infection, peginterferon alfa/ribavirin remains relevant in many resource-constrained settings. The non-randomized GUARD-C cohort investigated baseline predictors of safety-related dose reductions or discontinuations (sr-RD) and their impact on sustained virologic response (SVR) in patients receiving peginterferon alfa/ribavirin in routine practice. Methods: A total of 3181 HCV-mono-infected treatment-naive patients were assigned to 24 or 48 weeks of peginterferon alfa/ribavirin by their physician. Patients were categorized by time-to-first sr-RD (Week 4/12). Detailed analyses of the impact of sr-RD on SVR24 (HCV RNA

Original languageEnglish
Article numbere0151703
JournalPLoS One
Volume11
Issue number3
DOIs
Publication statusPublished - márc. 1 2016

Fingerprint

Hepatitis C virus
Ribavirin
Viruses
Hepacivirus
Safety
dosage
Patient treatment
chronic hepatitis C
antiviral agents
Chronic Hepatitis C
Virus Diseases
physicians
Antiviral Agents
RNA
Physicians
infection
Sustained Virologic Response
Therapeutics
methodology

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

@article{f0ccefd5acd5407d9a07b362e2bd320e,
title = "Impact of safety-related dose reductions or discontinuations on sustained virologic response in HCV-infected patients: Results from the GUARD-C Cohort",
abstract = "Background: Despite the introduction of direct-acting antiviral agents for chronic hepatitis C virus (HCV) infection, peginterferon alfa/ribavirin remains relevant in many resource-constrained settings. The non-randomized GUARD-C cohort investigated baseline predictors of safety-related dose reductions or discontinuations (sr-RD) and their impact on sustained virologic response (SVR) in patients receiving peginterferon alfa/ribavirin in routine practice. Methods: A total of 3181 HCV-mono-infected treatment-naive patients were assigned to 24 or 48 weeks of peginterferon alfa/ribavirin by their physician. Patients were categorized by time-to-first sr-RD (Week 4/12). Detailed analyses of the impact of sr-RD on SVR24 (HCV RNA",
author = "{GUARD-C Study Group Investigators} and Foster, {Graham R.} and Carmine Coppola and Moutaz Derbala and Peter Ferenci and Alessandra Orlandini and Reddy, {K. Rajender} and Ludovico Tallarico and Shiffman, {Mitchell L.} and Silke Ahlers and Georgios Bakalos and Tarek Hassanein and Jovan Basho and Gentian Shabanaj and Arjan Harxhi and Nabil Debzi and Nawel Afredj and Nawal Guessab and Nadir Mahindad and Hassene Mahiou and Magda Aissaoui and {Al Qameesh}, Jihad and {Al Ghandoor}, Zuhal and Collins Assene and Boris Bastens and Christian Brixko and Mike Cool and {De Galocsy}, Chantal and Jean Delwaide and Christophe George and Pierre Laukens and Veronique Lefebvre and Mulkay, {Jean Pierre} and Frederik Nevens and Benoit Servais and {Van Vlierberghe}, Hans and Yves Horsmans and Jean Henrion and Dirk Sprengers and Peter Michielsen and Stefan Bourgeois and Luc Lasser and Philippe Langlet and Geert Robaeys and Martinet, {Jean Paul} and Philippe Warzee and F. Szalay and G. Lengyel and B. Hunyady and A. Vincze and I. R{\'a}cz",
year = "2016",
month = "3",
day = "1",
doi = "10.1371/journal.pone.0151703",
language = "English",
volume = "11",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "3",

}

TY - JOUR

T1 - Impact of safety-related dose reductions or discontinuations on sustained virologic response in HCV-infected patients

T2 - Results from the GUARD-C Cohort

AU - GUARD-C Study Group Investigators

AU - Foster, Graham R.

AU - Coppola, Carmine

AU - Derbala, Moutaz

AU - Ferenci, Peter

AU - Orlandini, Alessandra

AU - Reddy, K. Rajender

AU - Tallarico, Ludovico

AU - Shiffman, Mitchell L.

AU - Ahlers, Silke

AU - Bakalos, Georgios

AU - Hassanein, Tarek

AU - Basho, Jovan

AU - Shabanaj, Gentian

AU - Harxhi, Arjan

AU - Debzi, Nabil

AU - Afredj, Nawel

AU - Guessab, Nawal

AU - Mahindad, Nadir

AU - Mahiou, Hassene

AU - Aissaoui, Magda

AU - Al Qameesh, Jihad

AU - Al Ghandoor, Zuhal

AU - Assene, Collins

AU - Bastens, Boris

AU - Brixko, Christian

AU - Cool, Mike

AU - De Galocsy, Chantal

AU - Delwaide, Jean

AU - George, Christophe

AU - Laukens, Pierre

AU - Lefebvre, Veronique

AU - Mulkay, Jean Pierre

AU - Nevens, Frederik

AU - Servais, Benoit

AU - Van Vlierberghe, Hans

AU - Horsmans, Yves

AU - Henrion, Jean

AU - Sprengers, Dirk

AU - Michielsen, Peter

AU - Bourgeois, Stefan

AU - Lasser, Luc

AU - Langlet, Philippe

AU - Robaeys, Geert

AU - Martinet, Jean Paul

AU - Warzee, Philippe

AU - Szalay, F.

AU - Lengyel, G.

AU - Hunyady, B.

AU - Vincze, A.

AU - Rácz, I.

PY - 2016/3/1

Y1 - 2016/3/1

N2 - Background: Despite the introduction of direct-acting antiviral agents for chronic hepatitis C virus (HCV) infection, peginterferon alfa/ribavirin remains relevant in many resource-constrained settings. The non-randomized GUARD-C cohort investigated baseline predictors of safety-related dose reductions or discontinuations (sr-RD) and their impact on sustained virologic response (SVR) in patients receiving peginterferon alfa/ribavirin in routine practice. Methods: A total of 3181 HCV-mono-infected treatment-naive patients were assigned to 24 or 48 weeks of peginterferon alfa/ribavirin by their physician. Patients were categorized by time-to-first sr-RD (Week 4/12). Detailed analyses of the impact of sr-RD on SVR24 (HCV RNA

AB - Background: Despite the introduction of direct-acting antiviral agents for chronic hepatitis C virus (HCV) infection, peginterferon alfa/ribavirin remains relevant in many resource-constrained settings. The non-randomized GUARD-C cohort investigated baseline predictors of safety-related dose reductions or discontinuations (sr-RD) and their impact on sustained virologic response (SVR) in patients receiving peginterferon alfa/ribavirin in routine practice. Methods: A total of 3181 HCV-mono-infected treatment-naive patients were assigned to 24 or 48 weeks of peginterferon alfa/ribavirin by their physician. Patients were categorized by time-to-first sr-RD (Week 4/12). Detailed analyses of the impact of sr-RD on SVR24 (HCV RNA

UR - http://www.scopus.com/inward/record.url?scp=84962170784&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84962170784&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0151703

DO - 10.1371/journal.pone.0151703

M3 - Article

C2 - 27018988

AN - SCOPUS:84962170784

VL - 11

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 3

M1 - e0151703

ER -